Cyclooxygenase-2 expression is associated with initiation of hepatocellular carcinoma, while prostaglandin receptor-1 expression predicts survival

AIM To determine whether cyclooxygenase-2 (COX-2) and prostaglandin E1 receptor (EP1) contribute to disease and whether they help predict prognosis. METHODS We retrospectively reviewed the records of 116 patients with hepatocellular carcinoma (HCC) who underwent surgery between 2008 and 2011 at our hospital. Expression of COX-2 and EP1 receptor was examined by immunohistochemistry of formalin-fixed, paraffin-embedded tissues using polyclonal antibodies. Possible associations between immunohistochemical scores and survival were determined. RESULTS Factors associated with poor overall survival (OS) were alpha-fetoprotein > 400 ng/mL, tumor size ≥ 5 cm, and high EP1 receptor expression, but not high COX-2 expression. Disease-free survival was not significantly different between patients with low or high levels of COX-2 or EP1. COX-2 immunoreactivity was significantly higher in well-differentiated HCC tissues (Edmondson grade I-II) than in poorly differentiated tissues (Edmondson grade III-IV) (P = 0.003). EP1 receptor immunoreactivity was significantly higher in poorly differentiated tissue than in well-differentiated tissue (P = 0.001). CONCLUSION COX-2 expression appears to be linked to early HCC events (initiation), while EP1 receptor expression may participate in tumor progression and predict survival.

[1]  Zhe Guo,et al.  Blood neutrophil-lymphocyte ratio predicts survival after hepatectomy for hepatocellular carcinoma: A propensity score-based analysis. , 2016, World journal of gastroenterology.

[2]  Jianru Xiao,et al.  P50-associated COX-2 extragenic RNA (PACER) overexpression promotes proliferation and metastasis of osteosarcoma cells by activating COX-2 gene , 2016, Tumor Biology.

[3]  Jie Su,et al.  COX-2 Promotes Migration and Invasion by the Side Population of Cancer Stem Cell-Like Hepatocellular Carcinoma Cells , 2015, Medicine.

[4]  Peng Zhang,et al.  Micro ribonucleic acid (RNA)-101 inhibits cell proliferation and invasion of lung cancer by regulating cyclooxygenase-2 , 2015, Thoracic cancer.

[5]  Ming Li,et al.  Artesunate inhibits the growth and induces apoptosis of human gastric cancer cells by downregulating COX-2 , 2015, OncoTargets and therapy.

[6]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[7]  G. Michalopoulos,et al.  Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells , 2006, Journal of cellular physiology.

[8]  Dan Sun,et al.  Expression of 15-hydroxyprostaglandin dehydrogenase and cyclooxygenase-2 in non-small cell lung cancer: Correlations with angiogenesis and prognosis , 2014, Oncology letters.

[9]  Min Zhang,et al.  Prostaglandin E2 promotes hepatocellular carcinoma cell invasion through upregulation of YB-1 protein expression. , 2014, International journal of oncology.

[10]  F. Shanahan,et al.  Targeting the EP1 receptor reduces Fas ligand expression and increases the antitumor immune response in an in vivo model of colon cancer , 2013, International journal of cancer.

[11]  Jeong‐Hoon Lee,et al.  Up-Regulation of Cyclooxygenase 2 and Matrix Metalloproteinases-2 and -9 in Cutaneous Squamous Cell Carcinoma: Active Role of Inflammation and Tissue Remodeling in Carcinogenesis , 2013, Annals of dermatology.

[12]  Hai Zhang,et al.  Prostaglandin E₂ receptor EP1-mediated phosphorylation of focal adhesion kinase enhances cell adhesion and migration in hepatocellular carcinoma cells. , 2013, International journal of oncology.

[13]  J. Erler,et al.  Lysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesis. , 2013, Cancer research.

[14]  Wei Wei,et al.  Prostanoid EP1 receptor as the target of (−)-epigallocatechin-3-gallate in suppressing hepatocellular carcinoma cells in vitro , 2012, Acta Pharmacologica Sinica.

[15]  Z. A. Abd Elmageed,et al.  Clinical relevance of cyclooxygenase-2 and matrix metalloproteinases (MMP-2 and MT1-MMP) in human breast cancer tissue , 2012, Molecular and Cellular Biochemistry.

[16]  Sun-Hee Kim,et al.  ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression. , 2011, Cancer research.

[17]  M. Hou,et al.  Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC) , 2011, Medical oncology.

[18]  Mu-Kuan Chen,et al.  Prostaglandin E2/EP1 Signaling Pathway Enhances Intercellular Adhesion Molecule 1 (ICAM-1) Expression and Cell Motility in Oral Cancer Cells* , 2010, The Journal of Biological Chemistry.

[19]  Y. Qiu,et al.  Adjuvant Therapy With Capecitabine Postpones Recurrence of Hepatocellular Carcinoma After Curative Resection: A Randomized Controlled Trial , 2010, Annals of Surgical Oncology.

[20]  T. Peng,et al.  Prostaglandin E2 upregulates survivin expression via the EP1 receptor in hepatocellular carcinoma cells. , 2010, Life sciences.

[21]  Xuetao Cao,et al.  Fas Signal Promotes Lung Cancer Growth by Recruiting Myeloid-Derived Suppressor Cells via Cancer Cell-Derived PGE21 , 2009, Journal of Immunology.

[22]  M. Notarbartolo,et al.  Prostaglandin E2 Receptors and COX Enzymes in Human Hepatocellular Carcinoma , 2009, Annals of the New York Academy of Sciences.

[23]  F. Shanahan,et al.  Prostaglandin E2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells , 2008, British Journal of Cancer.

[24]  M. Haberal,et al.  Lack of influence of cyclooxygenese-2 expression in hepatocellular carcinomas on patient survival. , 2008, Asian Pacific journal of cancer prevention : APJCP.

[25]  P. Schirmacher,et al.  Differential expression of E‐prostanoid receptors in human hepatocellular carcinoma , 2008, International journal of cancer.

[26]  G. Michalopoulos,et al.  Prostaglandin E2 Receptor EP1 Transactivates EGFR/MET Receptor Tyrosine Kinases and Enhances Invasiveness in Human Hepatocellular Carcinoma Cells , 2015, Journal of cellular physiology.

[27]  D. Qualtrough,et al.  Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. , 2006, Cancer research.

[28]  D. Kusewitt,et al.  Importance of the EP(1) receptor in cutaneous UVB-induced inflammation and tumor development. , 2006, The Journal of investigative dermatology.

[29]  M. Hull,et al.  Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? , 2004, Molecular cancer therapeutics.

[30]  T. Sugimura,et al.  Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. , 2001, Carcinogenesis.

[31]  G. FitzGerald,et al.  Genetic and pharmacological analysis of prostanoid receptor function. , 2001, The Journal of clinical investigation.

[32]  S. Narumiya,et al.  Inhibitory effect of a prostaglandin E receptor subtype EP(1) selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice. , 2000, Cancer letters.

[33]  S. Narumiya,et al.  Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. , 1999, Cancer research.

[34]  T. Kawaguchi,et al.  Expression of cyclooxygenase‐2 in human hepatocellular carcinoma: Relevance to tumor dedifferentiation , 1999, Hepatology.

[35]  S. Fan,et al.  Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. , 1999, Annals of surgery.

[36]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.